530 related articles for article (PubMed ID: 26182302)
1. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
7. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling of Small-Bowel Adenocarcinoma.
Schrock AB; Devoe CE; McWilliams R; Sun J; Aparicio T; Stephens PJ; Ross JS; Wilson R; Miller VA; Ali SM; Overman MJ
JAMA Oncol; 2017 Nov; 3(11):1546-1553. PubMed ID: 28617917
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.
Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ
J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188
[TBL] [Abstract][Full Text] [Related]
10. Genetic characterisation of molecular targets in carcinoma of unknown primary.
Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
12. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
14. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
[TBL] [Abstract][Full Text] [Related]
15. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
16. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
18. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.
Wang S; Chen R; Tang Y; Yu Y; Fang Y; Huang H; Wu D; Fang H; Bai Y; Sun C; Yu A; Fan Q; Gu D; Yi X; Li N
Front Oncol; 2020; 10():536. PubMed ID: 32373528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
